A new drug for fast-growing polycystic kidney disease
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney disease called ADPKD that is rapidly getting worse.
- You are between 18 and 55 years old.
- You have not taken tolvaptan or other ADPKD treatments in the last 3 months.
- You can feel thirst and have no trouble eating or drinking.
- You have not had surgery to remove kidney cysts or major surgery in the last 3 months.
- You are willing and able to follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests how a new experimental drug (JMKX003142) interacts with other medications in healthy volunteers. Researchers want to understand whether taking this drug with other common drugs is safe and effective.
This study is for healthy Chinese men to see how the study drug JMKX003142 is processed in the body. You will take the drug by mouth and by vein on separate days to measure how much gets into your blood and how it leaves your body.
This study checks how a new drug interacts with the body. It is for healthy volunteers to see if the drug is safe and how it works in the body.
This trial tests whether a new drug, JMKX003142, affects the heart's electrical activity (QTc interval) in healthy volunteers. It helps determine if the drug is safe for the heart before testing in patients.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Hear when a new ADPKD (Autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.